National Comprehensive Cancer Network

Educational Events & Programs

NCCN 4^th Annual Congress:
Hematologic Malignancies™
Educational Objectives

Following this Congress, participants should be able to:

• Outline the existing and emerging induction therapies for elderly patients with AML
• Formulate an appropriate treatment plan for patients with APL, from induction through maintenance, based on the available evidence
• Describe the clinical features of cancer stem cells and the implications of newly identified stem cell markers on the success of therapy for patients with CML
• State the various treatment options available for the management of patients with untreated and relapsed or refractory CLL
• Review the clinical results of investigational agents for the treatment of multiple myeloma
• Identify optimal induction therapies for patients with newly diagnosed multiple myeloma
• List clinical studies relating to the treatment of relapsed multiple myeloma in elderly patients
• Summarize some of the significant changes incorporated in the recently updated 2008 WHO classification of lymphomas
• Identify the prognostic significance of biomarkers and the role of gene expression profiling in DLBCL
• Describe the characteristics and management strategies of tumor lysis syndrome, a potentially fatal complication in hematological malignancies
• Summarize the role of platelet growth-promoting agents in the management of thrombocytopenia
• Outline the risks and benefits of ESAs and blood transfusions in the management of anemia in cancer patients
• Outline the clinical evidence demonstrating the value of intravenous iron supplementation in ESA therapy for patients with chemotherapy-induced anemia
• Describe the role of stem cell transplantation in the clinical management of patients with CML, lymphoma, or multiple myeloma including, where applicable, the use of nonmyeloablative strategies
• Review new data regarding the use of stem cell transplantation in patients with CML, lymphoma, or multiple myeloma

These objectives are subject to change as agenda is finalized.